DK
Therapeutic Areas
Hexamer Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SARS-CoV-2 Vaccines | COVID-19 | Pre-clinical |
| Neoantigen Based Cancer Therapy | Cancer | Pre-clinical |
Leadership Team at Hexamer Therapeutics
DC
Dr. Collin Collins, PhD
Chief Scientific Officer (CSO)
MR
Mr. Robert Bogden
Chief Executive Officer (CEO)